CURRICULUM VITAE Michael P

CURRICULUM VITAE Michael P. Pollastri, Ph.D. Northeastern University Department of Chemistry & Chemical Biology 102 Hurtig Hall; 360 Huntington Avenue Boston, MA 02115 USA (617) 373 2703; [email protected] http://www.northeastern.edu/pollastri

Education Brown University, Providence, RI Ph.D., Organic Chemistry, May 2004 Research Director: Kathlyn A. Parker, Ph.D., Professor of Chemistry Dissertation title: “Applications of ruthenium-catalyzed olefin metathesis to the preparation of fused ring systems” Duke University, Durham, NC M.S., Organic Chemistry, May 1998 Research Director: Ned A. Porter, Ph.D., James B. Duke Professor of Chemistry College of the Holy Cross, Worcester, MA A.B., With Honors in Chemistry, May 1995 Research Director: Timothy P. Curran, Ph.D., Associate Professor of Chemistry

Scientific Employment 2009- Northeastern University Department of Chemistry & Chemical Biology Professor (2017-) Department Chair (2016-) Interim Director, Barnett Institute for Chemical and Biological Analysis (2016-) Associate Professor, (2009-2017)

2015- Northeastern University Department of Bioengineering Affiliated Associate Professor

2010-2011 Boston University Department of Medicine, Boston, MA Adjunct Assistant Professor of Medicine

2007-2009 Boston University Department of Chemistry, Boston, MA Research Assistant Professor of Chemistry (2007-2009) Founding Director, Medicinal Chemistry & Core Synthesis Facility (2007-2009) Founding Director, Center for Molecular Discovery (2008-2009)

2006-2011 Brandeis University, Rabb School of Continuing Studies, Waltham, MA. Instructor

2003-2007 Pfizer Global Research & Development, Cambridge, MA Principal Scientist & Head of Chemical Technologies (2005-2007) Senior Scientist – Medicinal Chemistry (2003-2005)

1998-2003 Pfizer Global Research & Development, Groton, CT Associate Scientist (2003) Assistant Scientist (1998-2003) Awards & Honors Northeastern University Pre-Medical Program “Golden Pen” Award, 2017 Department of Residential Life Faculty Member of the Year nominee, 2016 Class of 2013 “Faculty Favorite” Nominated, Excellence in Teaching Award, 2013 University Excellence in Teaching Award, 2012 Department of Chemistry Service Award, 2012 Pfizer, Inc. RTC Blaze of Glory Award, 2005 Global R&D Achievement Award, 2003 Global R&D Excellence Award, 2003 Green Chemistry Award, 2003 Discovery - Above & Beyond Award, 2001, 2002 Phi Lambda Upsilon, Chemistry Honor Society, 1996 Joseph Cahill Award for Excellence in Chemistry (College of the Holy Cross), 1995

Research

PUBLICATIONS

Peer-reviewed publications. All last-author publications were also corresponding author. †NU undergraduate student advised by MPP; ‡NU graduate student advised or co-advised by MPP; ºpostdoctoral scholar supervised by MPP.

1. Absalon, S.; Blomqvist, K.; Rudlaff, R.; †DeLano, T.J.; Pollastri, M.P.; Dvorin, J.D. Calcium- dependent protein kinase 5 is required for release of egress-specific organelles in Plasmodium falciparum. Proceedings of the National Academy of Sciences. Revision Submitted. 2. Mehta, N.; Ferrins, L.; Leed, S.E.; Sciotti, R.J.; Pollastri, M.P. Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation. ACS Infectious Diseases, Submitted 3. ‡Klug, D.M.; Diaz-Gonazalez, R.; Perez-Moreno, G.; Ceballos-Perez, G.; Garcia-Hernandez, R.; Gomez-Perez, V.; Ruiz-Perez, L.; Gamarro, F.; Gonzalez-Pacanowska, D.; Navarro, M.; Pollastri, M.P. Early evaluation of a class of isatinoid inhibitors identified from a high-throughput screen of anti-sleeping sickness agents. Bioorganic & Medicinal Chemistry Letters, Under Revision. 4. Ferrins, L.; Pollastri, M.P. The importance of collaboration between industry, academics, and non- profits in tropical disease drug discovery ACS Infectious Diseases, In Press. Invited, peer reviewed perspective article. 5. ‡Woodring, J.L.; ‡Bachovchin, K.A.; †Brady, K.G.; †Gallerstein, M.F.; Erath, J.; Tanghe, S.; Leed, S.E.; Rodriguez, A.; Mensa-Wilmot, K.; Sciotti, R.J.; Pollastri, M.P. Towards Optimized Physicochemical Properties for 4-Anilinoquinazoline Inhibitors of Trypanosome Proliferation. European Journal of Medicinal Chemistry, 2017, 141, 446-459. 6. ‡Yuan, G.; Jankins, T.C.; Patrick, C.G.; Philbrook, P.; Sears, O.; Hatfield, S.; Sitovsky, M.; Vasdev, N.; Liang, S.H.; Ondrechen, M.J.; Pollastri, M.P.; Jones, G.B. Fluorinated adenosine A2a receptor antagonists inspired by preladenant as potential cancer immunotherapeutics. International Journal of Medicinal Chemistry, doi:10.1155/2017/4852537. 7. Kunz, S.; Balmer, V.; Sterk, G.J.; Pollastri, M.P.; Leurs, R.; Muller, N.; Hemphill, A.; Spycher, C. The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target. PLOS Neglected Tropical Diseases, 2017, 11, e0005981. 8. ‡Devine, W.; Thomas, S.; Erath, J.; ‡Bachovchin, K.; Lee, P.; Leed, S.; Rodriguez, A.; Sciotti, R.J.; Mensa-Wilmot, K.; Pollastri, M.P. Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites. ACS Medicinal Chemistry Letters, 2017, 8, 350. ACS Editors’ Choice Article 9. ‡Devine, W.; Diaz-Gonzalez, R.; Ceballos-Perez, G.; Rojas, D.; Satoh, T.; ‡Tear, W.; Ranade, R.M.; Barros-Alvarez, X.; Hol, W.G.J.; Buckner, F.S.; Navarro, M.; Pollastri, M.P. From cells, to mice, to target: Characterization of NEU-1053 (SB-443342) and its analogs for treatment of human African trypanosomiasis. ACS Infectious Diseases, 2017, 3, 225. 10. Guyett, P.; Behera, R.; Ogata, Y.; Pollastri, M.P.; Mensa-Wilmot, K Novel Effects of Lapatinib Revealed in the African Trypanosome using Hypothesis-Generating Proteomics and Chemical Biology Strategies. Antimicrobial Agents and Chemotherapy, 2017, 61, e01865. 11. Thomas, S.M.; Purmal, A.; Pollastri, M.P.; Mensa-Wilmot, K. Discovery of a carbazole-derived lead drug for human African trypanosomiasis. Scientific Reports, 2016, 6, 32083. 12. Guyett, P.J.; Xia, S.; Swinney, D.; Pollastri, M.P.; Mensa-Wilmot, K. Glycogen Synthase Kinase 3β Promotes Endocytosis of Transferrin in the African Trypanosome. ACS Infectious Diseases, 2016, 2, 518-528. 13. ‡Klug, D.M.; Gelb, M.H.; Pollastri, M.P. Repurposing Strategies for Neglected Disease Drug Discovery. Bioorganic and Medicinal Chemistry Letters (Digest). 2016, 26, 2569-2576. Invited article 14. ºAmata, E.; Xi, H.; Colmenarejo, G.; Gonzalez-Diaz, R.; Cordon-Obras, C.; Berlanga, M.; Manzano, P.; Erath, J.; Roncal, N.E.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Sciotti, R.J.; Navarro, M.; Pollastri, M.P. identification of “preferred” human kinase inhibitors for sleeping sickness lead discovery. Are some kinases better than others for inhibitor repurposing? ACS Infectious Diseases, 2016, 2, 180-186. 15. ‡Devine, W.; ‡Woodring, J.L.; ‡Swaminathan, U.; ºAmata, E.; ºPatel, G.; Erath, J.; Roncal, R.E.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Mensa-Wilmot, K.; Sciotti, R.J.; Pollastri, M.P. Protozoan parasite growth inhibitors discovered by cross-screening yields potent scaffolds for lead discovery. Journal of Medicinal Chemistry 2015, 58, 5522-5537. 16. ºAmata, E.; Bland, N.D.; Campbell, R.K.; Pollastri, M.P. Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). Tetrahedron Letters. 2015, 56, 2832-2835. 17. Kozakov, K.; Hall, D.R.; Jehle, S.; Luo, L.; ‡Ochiana, S.O.; †Jones, E.V.; Pollastri, M.P.; Allen, K.N.; Whitty, A.; Vajda, S. Ligand Deconstruction: Why Some Fragment Binding Positions Are Conserved and Others Are Not. Proceedings of the National Academy of Science 2015, 112, E2585-E2594. 18. Shivanna S.; Kolandaivelu, K.; Moshe, S.; Novikov, O.; Balcells, M.; Zheng A.; Weinberg, J.; Francis, J.; Pollastri, M.P.; Edelman, E.R.; Sherr, D.H.; Chitalia, V.C. The aryl hydrocarbon receptor is a critical regulator of tissue factor stability and is a novel anti-thrombotic target in uremia. Journal of the American Society of Nephrology. In Press. doi: 10.1681/ASN.2014121241 19. ‡Ochiana, S.O.; Bland, N.D.; Settimo, L.; Campbell, R.K.; Pollastri, M.P. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. Chemical Biology & Drug Design 2015, 85, 549-564. 20. ‡Woodring, J.L.; oPatel, G.; Erath, J.; Behera, R.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Sciotti, R.J.; Mensa-Wilmot, K.; Pollastri, M.P. Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria. MedChemComm. 2015, 6, 339-346. 21. ‡Silva, L.; ‡Tanner, A.; Merritt, C.; Stuart, K.; Pollastri, M.P. Protein kinases as druggable targets in protozoan parasites. Chemical Reviews, 2014, 114, 1280–11304. Invited review. 22. Diaz, R.; ºLuengo-Arratta, S.A.; ºSeixas, J.D.; ºAmata, E.; ‡Devine, W.; Cordon-Obras, C.; Rojas- Barros, D.I.; Jimenez, E.; Ortega, F.; Crouch, S.; Colmenarejo, G.; Fiandor, J.M.; Martin, J.J.; Berlanga, M.; Gonzalez, S.; Manzano, P.; Navarro, M.; Pollastri, M.P. Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign. PLOS Neglected Tropical Diseases. 2014, 8, e3253. 23. Parks, A.J.; Pollastri, M.P.; Hahn, M.E.; Stanford, E.A.; Franks, D.G; Haigh, S.E.; Narasimhan, S.; ºAshton, T.D.; †Hopper, T.G.; Kozakov, D.; Beglov, D.; Vajda, S.; Schlezinger, J.J.; Sherr, D.H. In Silico Identification of an Aryl Hydrocarbon Receptor (AhR) Antagonist with Biological Activity In Vitro and In Vivo. Molecular Pharmacology 2014, 86, 593-608. 24. ºAmata, E.; Bland, N.D.; †Hoyt, C.T.; Settimo, L.; Campbell, R.K.; Pollastri, M.P. Repurposing human PDE4 inhibitors for neglected tropical diseases: Design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2014, 24, 4084-4089. 25. Gaun, V.; Patchen, B.; Volovetz, J.; Zhen, A.W.; Andreev, A.; Pollastri, M.P.; Fraenkel, P.G. A chemical screen identifies small molecules that regulate hepcidin expression. Blood Cells, Molecules and Diseases 2014, 53, 231-240. 26. Galvin, B.D.; Li, Z.; Villemaine, E.; Poole, C.B.; Chapman, M.S.; Pollastri, M.P.; Wyatt, P.G.; Carlow, C.K.S. A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes. PLOS Neglected Tropical Diseases 2014, 8, e3145 27. Pollastri, M.P. Finding New Collaboration Models for Enabling Neglected Tropical Disease Drug Discovery. PLoS-Neglected Tropical Diseases 2014, 8, e2866. 28. ºSeixas, J.D.; ºLuengo-Arratta, S.A.; Diaz, R.; Saldivia, M.; Rojas-Barros, D.I.; Manzano, P.; Gonzalez, S.; Berlanga, M.; Smith, T.K.; Navarro, M.; Pollastri, M.P. Establishment of a structure-activity relationship of the NVP-BEZ235 chemotype as a lead for African sleeping sickness. Journal of Medicinal Chemistry 2014, 57, 4834-4848. 29. ºPatel, G.; Roncal, N.E.; Lee, P.J.; Leed, S.E.; Erath, J.; Rodriguez, A.; Sciotti, R.J.; Pollastri, M.P. Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery. MedChemComm 2014, 5, 655 – 658. 30. Lowe, M.M.; Mold, J.E.; Kanwar, B.; Huang, Y.; Louie, A.; Hahn, M.E.; Pollastri, M.P.; ºWang, C.; ºPatel, G.; Frank, D.G.; Schlezinger, J.; Sherr, D.; Silverstone, A.E.; McCune, J.M. Identification of an Endogenous Aryl Hydrocarbon Receptor Ligand That Drives Th22 Differentiation. PLoS One 2014, 9, e87877. 31. ‡Woodring, J.L.; Bland, N.D.; ‡Ochiana, S.O.; Campbell, R.K.; Pollastri, M.P. Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). Bioorganic and Medicinal Chemistry Letters 2013, 23, 5971-5974. 32. ºPatel, G.; ºKarver, C.E.; Behera, R.; Guyett, P.; †Edwards, P.; Roncal, N.E.; Mensa-Wilmot, K.; Pollastri, M.P. Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis. Journal of Medicinal Chemistry 2013, 56, 3820-3832. 33. Andriani, G.; ºAmata, E.; †Beatty, J.; †Clements, Z.; †Coffey, B.J.; Courtemanche, G.; ‡Devine, W.; Erath, J.; †Juda, C.E.; Wawrzak, Z.; Wood, J.; Lepesheva, G.I.; Rodriguez, A.; Pollastri, M.P. Antitrypanosomal lead discovery: Identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. Journal of Medicinal Chemistry 2013, 56, 2556-2567. 34. Katiyar, S.; Kufareva, I.; Behera, R.; Ogata, Y.; Pollastri, M.P.; Abagyan, R;. Mensa-Wilmot, K. Lapatinib-binding Protein Kinases in the African Trypanosome: A General Method for Identification of Targets for Kinase-Directed Drugs in a Cell. PloS One 2013, 8, e56150. 35. ‡Ochiana, S.O.; Pandarinath, V.; ‡Wang, Z.; Kapoor, R.; Ondrechen, M.J.; Ruben, L.; Pollastri, M.P. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing. European Journal of Medicinal Chemistry 2013, 62, 777-784. 36. ºWang, C.; ºAshton, T.D.; Gustafson, A.; Bland, N.D.; ‡Ochiana, S.O.; Campbell, R.K.; Pollastri, M.P. Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 1. Sildenafil analogs. Bioorganic and Medicinal Chemistry Letters 2012, 22, 2579-2581. 37. ‡Ochiana, S.O.; Gustafson, A.; Bland, N.D.; ºWang, C.; †Russo, M.J.; Campbell, R.K.; Pollastri, M.P. Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 2. Tadalafil analogs. Bioorganic and Medicinal Chemistry Letters 2012, 22, 2582- 2584. 38. Bland, N. D.; ºWang, C.; †Tallman, C.; Gustafson, A. E.; ‡Wang, Z.; ºAshton, T. D.; ‡Ochiana, S. O.; McAllister, G.; Cotter, K.; Fang, A. P.; Gechijian, G.; Garceau, N.; Gangurde, R.; Ortenberg, R.; Ondrechen, M. J.; Campbell, R. K.; Pollastri, M. P. Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness. Journal of Medicinal Chemistry 2011 54, 8188-8194. 39. Diaz-Gonzalez, R.; Kuhlmann, F.M.; Galan-Rodriguez, C.; Madeira da Silva,L.; ºKarver, C.E.; Beverley, S.M.; Rodriguez, A.; Navarro, M; Pollastri, M.P. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS- Neglected Tropical Diseases 2011, 5, e1297. 40. Doan, T. L.; Pollastri, M.P.; Walters, M.A.; Georg, G.I. Progress in drug repositioning: Old drugs, new opportunities. Annual Reports in Medicinal Chemistry 2011, 46, 385-401. Invited review. 41. Pollastri, M.P; Campbell, R.K. Target repurposing for neglected diseases. Future Medicinal Chemistry 2011, 3,1307-1315. Invited review 42. Shaw, B. F.; Arthanari, H.; Narovlyansky, M.; Durazo, A.; Frueh, D.P.; Pollastri, M. P.; Lee, A.; Bilgicer, B.; Gygi, S. P.; Wagner, G.; Whitesides, G. M. Neutralizing positive charges at the surface of a protein lowers its rate of amide hydrogen exchange without altering its structure or increasing its thermostability. Journal of the American Chemical Society 2010 132, 17411-17425. 43. Pollastri, M. P. “Overview of the Rule of Five.” Current Protocols in Pharmacology. John Wiley & Sons, Inc. 2010, 49, 9.12.1–9.12.8. Invited review 44. Pollastri, M. P.; Whitty, A.; Merrill, J. C., Tang, X. ºAshton, T. D.; Amar, S. Identification and Characterization of Kava-derived Compounds Mediating TNF-α Suppression. Chemical Biology and Drug Design 2009, 74, 121-128. 45. Bazin, M; Shi, H; Delaney, J.; Kline, B;, Zhu, Z.; Kuhn, C.; Berlioz, F.; Farley, K.; Fate, G.; Lam, W.; Walker, G.; Yu, L.; Pollastri, M.P. Efficient use of the iron ortho-nitrophenylporphyrin chloride to mimic biological oxidations of dimethylaminoantipyrine. Chemical Biology and Drug Design 2007, 70, 354-359. 46. Pollastri, M. P. “Development of continuous flow synthesis for production of compounds for medicinal chemistry”, ChemTracts—Organic Chemistry 2007, 20, 199-209. Invited review 47. Pollastri, M.P., Sagal, J.F., Chang, G., The Conversion of Alcohols to Halides Using a Filterable Phosphine Source. Tetrahedron Letters 2001, 35, 2459-2460. 48. Pollastri, M.P., Porter, N.A., McIntosh, T.J., Simon, S.A., Synthesis, Structure, and Thermal Properties of 1,2-Dipalmitoylgalloylglycerol (DPGG), A Novel Self-Adhering Lipid. Chemistry and Physics of Lipids 2000, 104, 67-74. 49. McIntosh, T.J., Pollastri, M.P., Porter, N.A., Simon, S.A, Polyphenols increase adhesion between lipid bilayers by forming interbilayer bridges, Basic Life Sciences 66(Plant Polyphenols 2) 1999, 451-470. 50. Jones, P.B., Pollastri, M.P., Porter, N.A., 2-Benzoylbenzoic Acid: A Photolabile Mask for Alcohols and Thiols. Journal of Organic Chemistry 1996, 61, 9455-9461. 51. Curran, T.P., Pollastri, M.P., Abelleira, S.M., Messier, R.J., McCollum, T.A., Rowe, C.G., Loss of the tert-Butyloxycarbonyl (Boc) Protecting Group Under Basic Conditions. Tetrahedron Letters 1994, 35, 5409-5412. 52. Curran, T.P., Smith, M.B., Pollastri, M.P., Cis-3,5-Dimethyl-3,5-Piperdinedicarboxylic Acid, An Amino Diacid Variant of Kemp’s Triacid. Tetrahedron Letters 1994, 35, 4515-4518.

Other Reviews and Invited Contributions 1. Pollastri, M.P. Jumping the industry-academic fence. Future Medicinal Chemistry 2013, 4, 25. 2. Discussion of the Uniting to Combat Neglected Tropical Diseases agreement. Current Medicinal Chemistry 2012, 4, 1383. 3. Pollastri, M.P. “Drug Discovery in the 21st Century” Future Medicinal Chemistry 2011, 16, 1975- 1977. 4. Schiffer, S. Anderson, A.C., Pollastri, M.P., Peet, N.P. “The Challenge of Developing Robust Drugs to Overcome Resistance.” Drug Discovery Today 2011, 16, 755-761.

Book Chapters 1. Pollastri, M.P.; Woodring, J. “Inhibitors of protozoan phosphodiesterases as potential therapeutic approaches for tropical diseases.” In Phosphodiesterases and Their Inhibitors, Liras, S; Bell, A., Eds . Wiley-VCH, Weinheim, Germany, 2014. 2. Pollastri, M.P.; Devine, W.G. “Microwave synthesis.” In Green Techniques for Organic Synthesis and Medicinal Chemistry. Zhang, W.; Cue, B., Eds. Wiley-VCH, Weinheim, Germany, 2012

Patents 1. Pollastri, M.P., Mehta, N., Devine, W., Woodring, J., Swaminathan, U., Mensa-Wilmot, K. “Protozoan parasite growth inhibitors”. US Patent Application No. 2015/0259331, 17 Sept 2015. 2. Lewis, K., Conlon, B., Nelson, M.L., Pollastri, M.P., Dahl, T.A. “Methods of eradicating bacterial cell populations.” PCT/US12/31882 3. Sherr, D.S., Pollastri, M.P., Schlezinger, J., Haigh Molina, S.E., Schaus, S.E., Giguere, J.R. “Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics.” PCT/US11/45526, U.S. Serial No. 13/812375 4. Chang, G., Didiuk, M. T. Finneman, J. I., Garigiapati, R. S., Kelley, R. M., Perry, D. A., Ruggeri, R. B., Bechle, B. M., Pollastri, M. P. “Preparation of 1,2,4-substituted-1,2,3,4-tetrahydro-and 1,2- dihydroquinoline and 1,2,3,4-tetrahydroquinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity.” WO 2004085401. 5. Bechle, B.M., Chang, G.C., Diduik, M., Garigipati, R.S., Kelley, R.M., Perry, D.A., Pollastri, M.P. Ruggeri, R.B. “Quinoline and quinoxaline compounds.” US11305874

Invited Presentations 1. Approaches, advances, and adventures in kinase inhibitor repurposing for tropical disease drug discovery. University of Kansas Department of Chemistry, Lawrence, KS (11 October 2017 2. Adventures in lead repurposing for neglected tropical diseases. Duke University Department of Chemistry, Durham, NC (3 October 2017) 3. Adventures in kinase inhibitor repurposing for tropical disease drug discovery. Northeastern University Department of Pharmaceutical Sciences, Boston, MA (21 September 2017) 4. Approaches for neglected disease drug discovery by repurposing kinase inhibitor leads. Organix, Inc., Woburn, MA (19 September 2017) 5. Efforts in kinase inhibitor lead repurposing for neglected tropical diseases. International Medicinal Chemistry Symposia of the Asian Federation for Medicinal Chemistry, Melbourne, Australia (Invited keynote, 23-26 July 2017) 6. Lead Repurposing as an effective approach for neglected tropical disease drug discovery. 6th Annual Drug Repositioning Conference, Chicago, IL (27-28 June, 2017) 7. Kinase inhibitor repurposing approaches to lead discovery for neglected tropical diseases. Towards New Therapeutics for Diseases of the Developing World Conference, Madrid, Spain (18-20 June 2017). 8. Approaches, advances (and adventures) in kinase inhibitor repurposing for tropical disease drug discovery. Medicinal Chemistry & Chemical Biology Division Meeting of the Royal Australian Chemistry Institute, Sydney, Australia (Plenary, 7-9 November 2016). 9. Efforts in kinase inhibitor lead repurposing for neglected tropical diseases. H3D Symposium, Capetown, South Africa (Plenary; 15-18 November 2016) 10. Approaches and adventures in kinase inhibitor repurposing for tropical disease drug discovery. Worcester Polytechnic Institute (26 October 2016) 11. Repurposing approaches for neglected tropical disease drug discovery. Georgetown University Department of Chemistry (19 April 2016). 12. Lead repurposing as a means to speed drug discovery for neglected tropical diseases. Bridgewater State University Department of Chemistry (18 March 2016). 13. Crowdsourced lead discovery: Accelerated neglected tropical disease medicinal chemistry using a distributed model. SLAS 2016, San Diego, CA (23-27 Jan 2016). 14. Neglected tropical disease drug discovery using a distributed drug discovery model. International Chemical Congress of Pacific Basin Societies (Pacifichem), Honolulu, HI (14-20 December 2015). 15. Enabling distributed neglected tropical disease drug discovery with the CDD Vault. CDD Vision Workshop at the 250th National Meeting of the American Chemical Society, Boston, MA (16-20 August 2015). 16. Efficient discovery of antiparasitic agents by a combination of kinase inhibitor repurposing and cross- pathogen screening. 15th Annual Centre for Host-Parasite Interactions Symposium, Montreal, Canada (8-9 June 2015). Keynote. 17. Repurposing kinase inhibitor chemotypes accelerates tropical disease drug discovery. 17th Annual Northeastern Student Chemistry Research Conference (18 April 2015). Keynote. 18. Streamlining tropical disease lead discovery by repurposing kinase inhibitor chemotypes. University of California – San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA (17 Feb 2015). 19. Repurposing kinase-targeting medicinal chemistry accelerates drug discovery for neglected tropical diseases, Brown University Department of Chemistry Seminar Series, Providence, RI (13 Feb 2015). 20. Accelerating tropical disease drug discovery by repurposing kinase inhibitor chemotypes, Cubist, Inc., Lexington, MA (18 Nov 2014). 21. Repurposing kinase targeted compounds as efficient leads for neglected tropical disease drug discovery, University of Minnesota Department of Medicinal Chemistry Student Selected Seminar, Minneapolis, MN (23 Sep 2014). 22. Launching antiparasitic programs via target repurposing, Walter Reed Army Institute of Research, Silver Springs, MD (30 June 2014). 23. Neglected tropical disease drug discovery: Repurposing kinase inhibitor chemotypes as antiparasitic agents. Colorado College Speakers on Innovation Lecture Series, Colorado Springs, CO (19 Jun 2014). 24. Neglected tropical disease drug discovery: Repurposing kinase inhibitor chemotypes as antiparasitic agents. University of Wisconsin Pharmaceutical Sciences Seminar Series, Madison, WI. (25 Apr 2014). 25. Neglected tropical disease drug discovery: Repurposing kinase inhibitor chemotypes as antiparasitic agents. Northwestern University Organic Chemistry Seminar Series, Evanston, IL. (24 Apr 2014). 26. Neglected tropical disease drug discovery: Repurposing kinase inhibitor chemotypes as antiparasitic agents. New York University Organic Chemistry Seminar Series, New York, NY. (22 Apr 2014). 27. Neglected tropical disease drug discovery: Repurposing kinase inhibitor chemotypes as antiparasitic agents. University of Washington Organic Chemistry Seminar Series, Seattle, WA. (9 Apr 2014). 28. Target repurposing accelerates drug discovery for neglected tropical diseases. The Scripps Research Institute, La Jolla, CA (14 Mar 2014). 29. Target repurposing accelerates drug discovery for neglected tropical diseases. University of California San Francisco Department of Pathology and Laboratory Medicine Seminar Series, San Francisco, CA (22 Nov 2013). 30. Target repurposing accelerates drug discovery for neglected tropical diseases. University of Kansas Chemistry Department Seminar Series, Lawrence, KS (21 Nov 2013). 31. Target repurposing accelerates drug discovery for neglected tropical diseases. University of Illinois Chemistry Seminar Series, Urbana-Champaign, IL (11 Nov 2013). 32. Target repurposing accelerates drug discovery for neglected tropical diseases. University of South Florida Chemistry Seminar Series, Tampa, FL (7 Nov 2013). 33. Discovering new drugs for neglected tropical diseases via target repurposing. College of the Holy Cross Chemistry Department Seminar Series, Worcester, MA (1 Nov 2013) 34. Target repurposing for neglected tropical disease drug discovery: Recycling kinase inhibitor chemical matter. Vertex, Inc., Cambridge, MA (29 October 2013). 35. Expediting drug discovery for neglected tropical diseases using target repurposing. University of Michigan Department of Medicinal Chemistry, Ann Arbor, MI (25 Oct 2013). 36. Target repurposing accelerates drug discovery for neglected tropical diseases. University of Pittsburgh Chemistry Department Seminar Series, Pittsburgh, PA (17 Oct 2013). 37. Target repurposing accelerates drug discovery for neglected tropical diseases. Vanderbilt University Chemistry Colloquium Series, Nashville, TN (7 Oct 2013). 38. Target repurposing accelerates drug discovery for neglected tropical diseases. University of Georgia Chemistry Department Seminar Series, Athens, GA (5 Sept 2013). 39. Target repurposing accelerates drug discovery for neglected tropical diseases. University of North Carolina Eshelman School of Pharmacy Seminar, Chapel Hill, NC (4 Sept 2013). 40. Accelerated antiparasitic drug discovery: Repurposing kinase inhibitor medicinal chemistry for neglected tropical diseases. GlaxoSmithKline, Waltham MA (10 May 2013) 41. Discovering new drugs for neglected tropical diseases via target repurposing. Norwich University College of Science and Mathematics Seminar, Northfield, VT (15 Apr 2013). 42. Addressing neglected tropical diseases by repurposing kinase medicinal chemistry. UMass- Dartmouth Chemistry Colloquium Series, Dartmouth, MA (14 Nov 2012). 43. Addressing neglected diseases: Tuning our drug discovery platform to remedy diseases of the poor. Northeastern University College of Science Colloquium, Boston, MA (12 Oct 2012). 44. Panel Participant at the Drug Discovery Workshop, Boston Symposium on Organic & Bioorganic Chemistry, Boston, MA (28 Sept 2012). 45. Neglected disease drug discovery using target repurposing strategies, Constellation Pharmaceuticals, Cambridge MA (11 Sept 2012). 46. Repurposing kinase-targeted medicinal chemistry for neglected tropical disease drug discovery, Wake Forest University Chemistry Seminar, Winston-Salem, NC (4 Apr 2012). 47. Repurposing kinase-targeted medicinal chemistry for neglected tropical disease drug discovery, Harvard Medical School Pharmacology Seminar, Boston, MA (3 Feb 2012). 48. Drug discovery for neglected diseases using target repurposing. New England Biolabs, Ipswich, MA (15 Dec 2011). 49. Drug discovery for neglected diseases using target repurposing. EMD-Serono, Billerica, MA (16 Nov 2011). 50. Target repurposing for neglected tropical disease drug discovery. Pfizer, Inc. Groton, CT (19 Aug 2011). 51. Institute for Therapeutics Discovery and Development Seminar Series, University of Minnesota, Minneapolis, MN (14 Jan 2011) 52. Inaugural Northeastern University AAPS Meeting, Boston, MA (20 May 2010) 53. Roxbury Community College STEM Seminar Series, Boston, MA (24 Apr 2010) 54. Northeastern Section Younger Chemists Cmte 2010 Career Day, Boston, MA (15 Feb 2010) 55. Northeastern University Pharmaceutical Sciences Colloquium, Boston, MA (19 Nov 2009) 56. UMass-Boston Chemistry Department Seminar Series, Boston, MA (15 Apr 2009) 57. University of New England Biomedical Seminar Series, Biddeford, ME (24 Mar 2009) 58. Griffith University Chemistry Seminar Series, Brisbane, Australia (16 Jan 2007) 59. Victorian College of Pharmacy, Parkville, Australia (13 Jan 2007) 60. Trinity College Chemistry Department Seminar Series, Hartford, CT (29 Sept 2006) 61. UMass Lowell Chemistry Department Seminar Series, Lowell, MA (1 Oct 2004) 62. Microwave Assisted Organic Synthesis Symposium, Boston, MA (5 Oct 2004)

Conference Presentations. (Oral presentations indicated by underlined title; presenting author noted by asterisk) 1. Ferrins, L;Klug, D.M.; Bag, S.; Tanghe, S.; Wiedman, J.; Thomas, S.M,; Rodriguez, A.; Sciotti, R.J.; Mensa-Wilmot K.; Pollastri, M.P.* Improvement of physicochemical properties of an anti- protozoal chemotype derived from lapatinib. Medicinal Chemistry Gordon Research Conference (7-11 August 2016) 2. Olego-Fernández, S.; Jadhav, G.P.; Colmenarejo, G.; de la Torre Arrieta, J.; Urquiza, I.P.; Fouchet, M.-H.; Berlanga, M.; Martin, J.J.; Manzano, M.P.; Pollastri, M.P.; de-Koning, H.; Campbell, R.K.* Discovery and initial characterization of a large hit family for Trypanosoma brucei phosphodiesterase PDEB1. Drug Discovery for Parasitic Diseases - Keystone Symposia, Tahoe City, CA (24-28 January 2016). 3. Pollastri, M.P. distributed drug discovery: collaborative target repurposing accelerates identification of new leads for neglected tropical diseases. 250th National Meeting of the American Chemical Society, Boston, MA (16-20 August 2015). 4. Klug, D.*; Diaz, R.; Cordon-Obras, C.; Rojas-Barros, D.I.; Navarro, M.; Pollastri, M.P. hit-to-lead optimization efforts of HTS hits for human African trypanosomiasis. 250th National Meeting of the American Chemical Society, Boston, MA (16-20 August 2015). 5. Devine, W.;* Cordon-Obras, C.; Rojas-Barros, D.I.; Navarro, M.; Pollastri, M.P. Structure-activity relationship studies of SB-443342 (NEU-1053), a potent inhibitor of Trypanosoma brucei proliferation. 250th National Meeting of the American Chemical Society, Boston, MA (16-20 August 2015). 6. DeLano, T.;* Seixas, J.D.; Luengo-Arratta, S.A.; Diaz, R.; Navarro, M.; Pollastri, M.P. Assessment of NEU-1090, an analog of NVP-BEZ235, as a new lead and tool compound for human African trypanosomiasis. 250th National Meeting of the American Chemical Society, Boston, MA (16-20 August 2015). 7. Silva, L.;* Diaz, R.; Cordon-Obras, C.; Rojas-Barros, D.I.; Navarro, M.; Pollastri, M.P. Trypanosoma brucei growth inhibitors: High-throughput screening hit exploration. 250th National Meeting of the American Chemical Society, Boston, MA (16-20 August 2015). 8. Mehta, N.; Devine, W.; Woodring, J. L.; Swaminathan, U.; Thomas, S.M.; Mensa-Wilmot, K.; Pollastri, M.P.* Neglected tropical disease drug discovery: progress in properties and efficiency- based optimization of a repurposed kinase inhibitor chemotype for human African trypanosomiasis. Medicinal Chemistry Gordon Research Conference (2-6 August 2015) 9. Pollastri, M.P Data sharing for neglected tropical disease drug discovery: Creating a framework for reducing redundancy and improving global collaboration. Consortium of Universities for Global Health Conference. Boston, MA USA (25-28 March 2015). 10. Pollastri, M.P Hit-to-lead medicinal chemistry for African sleeping sickness. 12th Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO USA (25-29 January 2015). 11. *Silva, L; Diaz, R.; Luengo-Arratta, S.A.; Seixas, J.D.; Amata, E.; Devine, W.; Cordon-Obras, C.; Rojas-Barros, D.I.; Jimenez, E.; Ortega, F.; Crouch, S.; Colmenarejo, G.; Fiandor, J.M.; Martin, J.J.; Berlanga, M.; Gonzalez, S.; Manzano, P.; Navarro, M.; Pollastri, M.P. Hit-to-lead optimization of kinase-targeted inhibitors of Trypanosoma brucei growth. Society for Advancement of Hispanics/Chicanos and Native Americans in Science Annual Meeting, Los Angeles, CA USA (16 October 2014) 12. *Silva, L.; Diaz, R.; Luengo-Arratta, S.A.; Seixas, J.D.; Amata, E.; Devine, W.; Cordon-Obras, C.; Rojas-Barros, D.I.; Jimenez, E.; Ortega, F.; Crouch, S.; Colmenarejo, G.; Fiandor, J.M.; Martin, J.J.; Berlanga, M.; Gonzalez, S.; Manzano, P.; Navarro, M.; Pollastri, M.P. Hit-to-lead optimization of kinase-targeted inhibitors of Trypanosoma brucei growth. Boston Society for Organic and Bioorganic Chemistry, Boston, MA USA (8 October 2014) 13. *Pollastri, M.P. A new model for neglected tropical disease drug discovery data sharing: an invitation to the NTD research community. International Society for Neglected Tropical Diseases, Drug Discovery & Development conference. Wellcome Trust. London, UK. May 2014. 14. *Pollastri, M.P. Drug discovery for neglected tropical diseases using a distributed research model. Academic Drug Discovery Consortium Conference, Nashville, TN, USA October 2013. 15. *Pollastri, M.P.; Diaz, R.; Luengo-Arratta, S.A.; Seixas, J.D.; Cordon, C.; Rojas, D.; Berlanga, M.; Colmenarejo, G.; Fiandor, J.M.; Gonzalez, S.; Manzano, P.; Martin, J.J.; Navarro, M. High- throughput screening of a kinase-targeted library at the GlaxoSmithKline OpenLab: Identification and characterization of hundreds of anti-trypanosomal hit compounds and opportunities for “open- source” optimization. Medicinal Chemistry Gordon Research Conference, New London, NH, USA. August 2013. 16. *Pollastri, M.P.; Diaz, R.; Luengo-Arratta, S.A.; Seixas, J.D.; Berlanga, M.; Colmenarejo, G.; Fiandor, J.M.; Gonzalez, S.; Manzano, P.; Martin, J.J.; Navarro, M. High-throughput screening of a kinase-targeted library at the GlaxoSmithKline OpenLab: Identification and characterization of hundreds of anti-trypanosomal hit compounds and opportunities for “open-source” lead optimization. Kinetoplastid Cell and Molecular Biology Meeting, Woods Hole, MA, USA. April 2013. 17. *Pollastri, M.P. Antiparasitic drug discovery using a hybrid open model Boston area Antimicrobial Research Network. Waltham, MA. November 2013. 18. *Wamai, R.G.; Wangombe, J.; Ogembo, J.G.; Pollastri, M.P.; Nyakundi, H.; Ogutu, B.; Mutonga, D.; Muchiri, E.; Wasunna, M.; Yoos, A.; Oduwo, G. Prevalence of visceral leishmaniasis in East Pokot District; An Epidemiological and Community Interactions Survey. 61st Annual ASTMH National Meeting, Atlanta, GA, USA. November 2012. 19. *Pollastri, M.P. Repurposing kinase drug discovery for neglected tropical diseases: an opportunity for open source drug discovery. 1st Annual Meeting of the International Chemical Biology Society. Cambridge, MA. October 2012. 20. *Pollastri, M.P. Repurposing kinase medicinal chemistry for neglected diseases caused by protozoan parasites. Discovery on Target – Novel Strategies in Kinase Inhibitors. Boston, MA. October 2012. Invited. 21. *Pollastri, M.P. Global health as a cross-disciplinary, internationally collaborative challenge. MM Indo-US Educators Summit 2013. July 2013. Invited. 22. *Pollastri, M.P. Antiparasitic drug discovery using a hybrid open mode. American Chemical Society Central Regional Meeting. May 2013. Invited 23. Patel, G.; Karver, C.E; Behera,R.; Kufareva, I.; Abagyan, R.; Mensa-Wilmot,K.; *Pollastri, M.P. Optimization of a human protein kinase inhibitor scaffold for a neglected disease: A structure- activity relationship study of lapatinib analogs as anti-trypanosomal lead drugs. Gordon Research Conference, Medicinal Chemistry, New London, NH.August 2012. 24. *Ochiana, S.; Pandarinath, V.; Wang, Z.; Ondrechen, M.J.; Ruben, L.; Pollastri, M.P. Design and synthesis of anti-trypanosomal drugs based on the 1,4,5,6 tetrahydropyrrolo [3,4-c]pyrazole scaffold via target repurposing. 243rd ACS National Meeting, San Diego, CA. March 2012. 25. *Wang, Z.; Ochiana, S.; Pandarinath, V.; Ruben, L.; Ondrechen, M.J.; Pollastri, M.P. Identification of small molecule inhibitors of the trypanosomal kinase TbAUK1 based on comparative modeling. 243rd ACS National Meeting, San Diego, CA. March 2012. 26. *Pollastri, M.P. Repurposing kinase-targeted medicinal chemistry for neglected tropical disease drug discovery. Encouraging Development of Therapeutics for Neglected Diseases, Philadelphia, PA. March 2012. 27. Ochiana, S.O.; Pandarinath, V.; Wang, Z.; Ondrechen, M.J.; Ruben, L.; *Pollastri, M.P. Optimization of a human Aurora kinase inhibitor chemotype for selective anti-trypanosomal activity. Drug Discovery for Protozoan Parasites Keystone Conference. February 2012 28. *Pollastri, M.P. Cloud-based data management in an academic drug discovery environment. Electronic Notebooks Online Conference. December 2011. Invited. 29. *Ochiana, S.O; Wang, C.; Bland, N.D.; Woodring, J.L.; Wang, Z.; Ondrechen. M.J.; Gustafson, A.; Seebeck, T.; Kunz, S.; Campbell, R.K.; Pollastri. M.P. Target repurposing: Evaluation and optimization of human phosphodiesterase inhibitors as a starting point for inhibition of trypanosomatid phosphodiesterases, Gordon Research Conference, Bioorganic Chemistry, Andover, NH, June, 2011. 30. *Pollastri, M.P.; Diaz-Gonzalez, R.; Kuhlman, F.M.; Galan-Rodriguez, C.; Madeira da Silva, L.; Karver, C.; Beverley, S.; Rodriguez, A.; Navarro, M. Target repurposing: Identification of trypanosomal TOR/PI3K as a therapeutic approach. Kinetoplastid Molecular Cell Biology Conference, Woods Hole, MA, 2011. 31. *Bland, N.D.; Gustafson, A.E.; Wang, C.; Ochiana, S.O.; Pollastri, M.P.; Campbell, R.K. Repurposing human phosphodiesterase inhibitors as a route to developing anti-trypanosomal drugs. Kinetoplastid Molecular Cell Biology Conference, Woods Hole, MA. April 2011. 32. *Ochiana, S.; Ondrechen, M.J.; Pandarinath, V.; Pollastri, M.P.; Ruben, L.; Wang, Z. Design and synthesis of trypanosomal Aurora kinase inhibitors based on the 1,4,5,6-tetrahydropyrrolo[3,4- c]pyrazole scaffold for treatments for African Sleeping Sickness. Northeastern University Research and Scholarship Expo. April 2011. 33. *Wang, Z.; Ondrechen, M.J.; Ochiana, S.; Pollastri, M.P. Homology modeling and docking of TbAUK1 – Computational guidance for the development of a T. brucei therapeutic. Northeastern University Research and Scholarship Expo. April 2011. 34. *Hopper, T.; Parks, A.; Pollastri, M.P.; Sherr, D. Preparation and assessment of flavone derivatives as aryl hydrocarbon receptor ligands. Northeastern University Research and Scholarship Expo. April 2011. 35. *Pollastri, M.P. Target repurposing for neglected tropical diseases: A distributed drug discovery model. National Institute of Allergy and Infectious Disease Workshop: Neglected Tropical Diseases: Defining Opportunities to Accelerate Translational Research. Bethesda, MD. Mar 2011. Invited. 36. *Pollastri, M.P. Target repurposing for neglected tropical disease drug discovery: Translating pharma approaches to an academic environment. International Conference on Chemistry for Mankind: Innovative Ideas in Life Sciences, Nagpur India. February 2011. Invited plenary speaker & session chair. 37. *Pollastri, M.P. Target repurposing for neglected tropical disease drug discovery: Translating pharma approaches to an academic environment. Indian Society of Chemists and Biologists Conference, Rajkot India. February 2011. Invited plenary speaker. 38. *Pollastri, M.P. Distributed drug discovery for neglected tropical diseases: Translating pharma approaches to an academic environment. Fourth Annual Collaborative Drug Discovery Community Meeting for Catalyzing Humanitarian and Commercial Drug Discovery Research, San Francisco, CA. October 2010. Invited. 39. *Pollastri, M.P. Neglected disease drug discovery: the sustainability mandate.3rd International Symposium on Green Processing in the Pharmaceutical & Fine Chemical Industries, Boston, MA. Oct 2010. Invited. 40. *Bland, N.D.; Gustafson, A.E.; Wang, C.; Pollastri, M.P.; Campbell, R.K. The development of phosphodiesterase inhibitors for the treatment of sleeping sickness. 21st Molecular Parasitology Meeting, Woods Hole, MA, September 2010. 41. *Gustafson, A.E.; Bland, N.D.; Wang, C.; Ma, H.H.L.; Tallman, C.; Pollastri, M.P.; Campbell, R.K. The development of phosphodiesterase inhibitors for the treatment of sleeping sickness. 21st Molecular Parasitology Meeting, Woods Hole, MA, September 2010. 42. *Pollastri, M.P. Cloud-based informatics in academic drug discovery. Cambridgesoft User Group Meeting, Boston, MA. August 2010. Invited 43. *Snedeker, C.M.; Bradner, J.E.; Estiu, G.; Horn, D.; Qi, J.; Wiest, O. Wang, Q.-P.; Pollastri, M.P. Parachute strategy for drug discovery: Design and synthesis of trypanosomal histone deacetylase inhibitors towards trypanosomal disease therapeutics. 240th ACS National Meeting, Boston, MA, United States, August 2010. 44. *Ochiana, S.O.; Ruben, L.; Hubbard, J.G.; Ondrechen, M.J.; Pollastri, M.P. Inhibitors of trypanosomal Aurora kinases as an approach for treatments of African sleeping sickness. 240th ACS National Meeting, Boston, MA, United States, August 2010. 45. *Wang, C.; Campbell, R.K.; Gustafson, A.; Bland, N.D.; Tallman, C.; Russo, M.; Pollastri, M.P. Parachute strategy for drug discovery: Design and synthesis of trypanosomal phosphodiesterase inhibitors towards African sleeping sickness therapeutics. 240th ACS National Meeting, Boston, MA, United States, August 2010. 46. *Wang, Z.; Hubbard, C.E.; Ondrechen, M.J.; Pollastri, M.P. Modeling trypanosomal TOR kinase domains: Implications for the design of anti-parasitic drugs. 240th ACS National Meeting, Boston, MA, United States, August 2010. 47. *Hubbard, C.E.; Beverley, S.M.; Diaz, R.; Madeira da Silva L.; Navarro M.;, Ondrechen M.J.; Wang, Z.; Pollastri, M.P. Trypanosomal target of rapamycin: Repurposing of mammalian TOR inhibitors for neglected disease drug discovery. 240th ACS National Meeting, Boston, MA, United States, August 2010. 48. Karver, C.E.; Diaz, R.; Madeira da Silva, L.; Kuhlmann, M.; Galan-Rodriguez, C.; Navarro, M.; Beverley, S.M.; Rodriguez, A.; *Pollastri, M.P. Drug target repurposing as a rapid inroads into neglected tropical disease therapeutics: Trypanosomal TOR inhibitors. Medicinal Chemistry Gordon Research Conference, New London, NH 2010. 49. *Pollastri, M.P. Discovery of trypanosomal PDE inhibitors via target repurposing: A parachute approach to neglected disease drug discovery. Cyclic Nucleotide Phosphodiesterase Gordon Research Conference, Waterville Valley, NH 2010. Invited 50. *Wang, J.; Ondrechen, M.J.; Pollastri, M.P. Modeling Trypanosomal TOR Kinase Domains: Implications for the Design of Anti-Parasitic Drugs. Intelligent Systems for Molecular Biology (ISMB), international conference of the International Society for Computational Biology (ISCB), Boston, MA, July 11, 2010. 51. *Pollastri, M.P.; Beverley, S.M.; Bradner, J.E.; Campbell, R.K.; Horn, D.; Navarro, M.; Ruben,L.; Wang, C.C. Repurposing human drug discovery: Development of human gene family-based screening sets for parasitology research. Global Worming Conference, Boston, MA, 2010. 52. *Pollastri, M.P. Workflow and data in an academic medicinal chemistry lab. Cambridgesoft Cloud Computing Seminar, Boston, MA, April 2010. Featured speaker 53. *Wang, C.; Campbell, R.K.; Gustafson, A.; Tallman, C.; Russo, M.; Pollastri, M.P. The Parachute Strategy For Drug Discovery: Design and Synthesis of Trypanosomal Phosphodiesterase Inhibitors towards African Sleeping Sickness Therapeutics. Northeastern University Research and Scholarship Expo. April 2010. 54. *Hubbard, C.E.; Beverley, S.M.; Navarro, M.; Pollastri, M.P. Discovery of new treatments for neglected infectious diseases: Drug repurposing targeted towards the inhibition of trypanosomal TOR. Northeastern University Research and Scholarship Expo. April 2010. 55. *Snedeker, C.; Horn, D.; Wiest, O.; Bradner, J.E., Pollastri, M.P. The parachute strategy for drug discovery: Design and synthesis of trypanosomal histone deacetylase inhibitors towards trypanosomal disease therapeutics. Northeastern University Research and Scholarship Expo. April 2010. 56. *Ochiana, S.O.; Ondrechen, M.J.; Ruben, L.; Pollastri, M.P. Inhibitors of trypanosomal Aurora kinases as an approach for treatments of African sleeping sickness. Northeastern University Research and Scholarship Expo. April 2010. 57. *Pollastri, M.P.; Ashton, T.D.; Cotter, K.; Fang, A.P.; Gechijian, L.; Gustafson, A.; Russo, M.; Wang, C.; Campbell, R.K. Parachute drug discovery for neglected disease: Benchmark screening of human phosphodiesterase inhibitors against TbbPDEB1 and B2. 20th Molecular Parasitology Meeting, Woods Hole, MA. September 2009. 58. *Pollastri, M.P.; Beverley, S.M.; Bradner, J.E.; Campbell, R.K.; Horn, D.; Navarro, M.; Ruben,L.; Wang, C.C. Repurposing human drug discovery: Development of human gene family-based screening sets for parasitology research. 20th Molecular Parasitology Meeting, Woods Hole, MA. September 2009. 59. *Campbell, R.K.; Al-Lazikani, B.; Overington, J.P.; McAllister, G.; Chellammal, S.; Pollastri, M.P. Matching drug discovery programs to malaria. 20th Molecular Parasitology Meeting, Woods Hole, MA. September 2009. 60. McAllister, G.; Al-Lazikani, B.; Overington, J.P.; Chellammal, S.; Pollastri, M.P., *Campbell, R.K. Drug discovery space for African sleeping sickness, Chagas disease, and visceral leishmaniasis. 20th Molecular Parasitology Meeting, Woods Hole, MA. September 2009 61. *Pollastri, M.P.; Lee, K.; Campbell, R.; Garceau, N.; Gridley, S.; Ortenberg, R. Parachute drug discovery for neglected disease: Development strategies for inhibitors of trypanosomal PDEB1 and PDEB2. 19th Molecular Parasitology Meeting, Woods Hole, MA. September 2008. 62. *Pollastri, M.P. Progress in the Commercialization of Micro Process Technology - Panel Discussion. 10th International Conference on Microreaction Technology, AIChE Spring National Meeting, New Orleans, LA. April 2008. Invited panelist 63. *Zhu, Z.; Shalaeva, M.; Pollastri, M.P.; Stanton, R.V. Tautomer stability and pKa evaluation. 234th ACS National Meeting, Boston, MA, August 2007. 64. *Pollastri, M.P.; Walters, E.; Bazin, M.; Otte, D.A.; Nugent, R.A. Developing New Chemical Technologies at the RTC – A PGRD Testing Ground, 6th Pfizer Medicinal Chemistry Symposium. 2005. 65. *Pollastri, M. P.; Otte, D. A.; Wynn, T.A.; Ding, Y.-H.; Kohls, D.; Low, S.; Soulard, P.; McLaughlin, M.; Xi, H.; Kuhn, C.; Rennie, G.; Springer, S.; Johnson, T.; Delaney, J. Development of dynamic combinatorial chemistry as a novel hit-to-lead methodology, 6th Pfizer Medicinal Chemistry Symposium, 2005. 66. *Pollastri, M. P.; Otte, D. A.; Wynn, T.A.; Ding, Y.-H.; Kohls, D.; Low, S.; Soulard, P.; McLaughlin, M.; Xi, H.; Kuhn, C.; Rennie, G.; Springer, S.; Johnson, T.; Delaney, J. Development of dynamic combinatorial chemistry as a novel hit-to-lead methodology, Groton Chemistry Forum, Groton, CT, 2005 67. Pollastri, M. P. Microwave-mediated synthesis: A green chemistry technology. 229th ACS National Meeting, San Diego, CA, 2005. 68. *Pollastri, M.P.; Sagal, J.F.; Chang, G. Conversion of alcohols to halides using a filterable source of phenylphosphine. 218th ACS National Meeting, New Orleans, LA, 1999. 69. Curran, T.P.; *Pollastri, M.P.; Abelleira, S.M.; Messier, R.J.; McCollum, T.A.; Rowe, C.G. Rearrangement of the tert-butyloxycarbonyl (Boc) Protecting Group Under Basic Conditions. 209th National Conference of the American Chemical Society, San Diego, CA, 1994.

Media Features 1. Quoted in Science NewsFocus article: Leslie, M. “Drug developers finally take aim at a neglected disease.” Science 2011 333, 933. 2. Northeastern News Feature Articles  “Crowdfunding drug discovery.” 28 October 2013 http://www.northeastern.edu/news/2013/10/michael-pollastri-microryza/  “Global Health Initiative to address neglected tropical diseases.” 16 October 2012 http://www.northeastern.edu/news/2012/10/global-health-initiative-to-address-neglected- tropical-diseases/  “iNSolution: A cure for sleeping sickness?” 16 August 2012. http://www.northeastern.edu/insolution/health/2012/08/unfreakingbelieveable/  “A pioneering partnership to cure cystic fibrosis.” 23 February 2012 http://www.northeastern.edu/news/stories/2012/02/cf.html  “A partnership to cure sleeping sickness.” 20 January 2012. http://www.northeastern.edu/news/stories/2012/01/pollastri.html  “Targeting diseases beyond our borders.” 28 September 2011. http://www.northeastern.edu/news/stories/2011/09/kenya.html  “Calling attention to neglected diseases.” 24 March 2011. http://www.northeastern.edu/news/stories/2011/03/neglected_diseases.html 3. An interview regarding methods for data sharing for neglected diseases, 16 February 2012. https://www.collaborativedrug.com/buzz/2012/02/15/dr-michael-pollastri-northeastern- university/ 4. Discussion of the industry-to-academia career switch, 15 March 2012 http://www.pharmamanufacturing.com/articles/2012/044.html 5. Featured in “Open-source cures for tropical diseases” Wired-UK, November 2012. 6. Quoted in “Seasoned drugs offer therapeutic goldmine” Smith, C. Genetic Eng. & Biotech. News, 2013, 33, 1. 7. Featured in Northeastern Magazine, “Man on a Mission” 12/2013 8. Featured in the Northeastern University “Making Tomorrow Happen” campaign, 2013. 9. Invited guest blog: PBS NovaNext “What drug researchers can learn from a Kenyan clinic,” 2014. http://www.pbs.org/wgbh/nova/next/body/neglected-disease-drug-discovery/

Research Funding Active research funding 1. Crowdfunding. “Improving collaborations for neglected tropical diseases.” Start Date: 01/01/2014. Total Costs: $25,031. https://experiment.com/projects/improving-collaborations-for-neglected- tropical-diseases. Role: PI 2. NIH R21AI127594-01. “Lead optimization of agents targeting multiple kinetoplastid parasites.” Period 12/09/2016-11/30/2018. Total costs: $263,674. Role: PI (multi-PI) (R21/R33 Mechanism; R33 phase, if funded, will extend to 11/30/2021, totaling $1,145924). Role: PI 3. NIH R01AI114685. “Hit-to-lead discovery for sleeping sickness via industry-academic partnership.” Period 12/01/2014-11/30/2019. Total Costs: $2,477,509. Role: PI (multi-PI). 4. NIH R01AI124046-01. “Hit-to-lead optimization for sleeping sickness drug discovery.” Period 08/19/2016 – 07/31/2020. Total costs: $2,610,171; Role: PI (multi-PI). 5. Bill & Melinda Gates Foundation (subcontract from the Structural Genomics Consortium). “Structure-guided drug discovery for tuberculosis and malaria: the Structure-Guided Drug Discovery Coalition (SDDC).” Period 01/05/2015-01/31/2018. Total Costs: $417,533. Role: PI. 6. TC-164. T. brucei drug discovery: ADMET and PK support for hit-to-lead optimization. Agency: Tres Cantos OpenLab Foundation; Period 03/22/2016-03/21/2018; Total Costs: $144,812. Role: PI 7. NIH 1R01AI126311-A1. “Curaxin-137, A new lead for anti-trypanosome drug discovery.” Period 07/14/2017-06/30/2021. Total costs: $2,670,563. Role: PI (multi-PI)

Completed funding 1. Ignition Award. “Discovery of therapeutics for neglected diseases by repurposing established targets in drug discovery” Period 11/01/2008-10/31/2009. Total Costs: $25,000 Role: PI 2. NIH R01AI082577-01S1. “Validation and development of trypanosomal phosphodiesterase inhibitors for treatment of sleeping sickness – ARRA Summer Supplement”. Period 05/01/2009-09/01/2010. Total Costs: $64,833. Role: PI (multi-PI) 3. NIH R01GM064700-07S1. “Computational Mapping of Proteins for Binding of Ligands” Period 10/01/2009-9/30/2010. Total Costs (NEU subcontract): $49,574. Role: co-I 4. Ignition Award (Subcontract from Boston University). “Selective Aryl Hydrocarbon Receptor (AhR) Modifiers as Novel Breast Cancer Therapeutics” Period 6/01/2010-5/31/2012. Total Costs (NEU subcontract): $16,707. Role: co-PI 5. TC-007. Discovery of trypanosomal TOR/PI3K inhibitors. Agency: GlaxoSmithKline; Period 07/01/2011-3/31/2013; Total Costs: $510,441 funded via CSIC. Role: PI 6. Northeastern University Tier 1 Internal Grant. (co-PI). “Neglected Tropical Diseases in Kenya“ Period 07/01/2011-09/30/2013. Total Costs: $100,000. Role: co-PI 7. Northeastern University Tier 1 Internal Grant. (co-PI). “Establishment of a target repurposing screening set. “ Period 07/01/2012-09/30/2013. Total Costs: $50,000. Role: PI 8. NIH R01AI082577. “Validation and development of trypanosomal phosphodiesterase inhibitors for treatment of sleeping sickness.” Period 04/01/2009-03/31/2015. Total Costs: $ 2,681,235. Role: PI (multi-PI). 9. Flatley Discovery, Inc. “Hit-to-lead follow-up medicinal chemistry for cystic fibrosis.” Period 07/01/2011-10/31/2015. Total costs: $692,435. Role: PI 10. TC-050 “Modulation of trypanosomal cAMP signaling for sleeping sickness therapeutic discovery.” Agency: GlaxoSmithKline; Period 07/01/2012-10/31/2015; Total Costs: $516,539, funded via Univ. of Glasgow. Role: co-PI 11. NIH R56AI099476. “Lead Optimization of Lapatinib Analogs for Human African Trypanosomiasis.” Period 08/19/2014‐07/31/2016. Total Costs: $ 661,912. Role: PI (multi‐PI).

Service Professional Affiliations and Service New York Academy of Medicine, Member (2012-) The Institute for Drug Resistance, Founding Member (2009-) (Executive Board member 2010-2012) NEACS Organic Symposium Organizing Committee, Member (2009-2010) Biotage Industrial Advisory Board, Member (2005-2008) New York Academy of Science, Member (2004-2005) American Chemical Society, Member (1994-) Connecticut Valley Section of the ACS, Executive Board Member (1999-2003)

Service to the University and Department 1. Faculty Advisor: END7 Student Group (2017-) 2. Faculty Advisor: National Organization for Rare Diseases Student Affiliate Group (2017-) 3. Chair, Department of Chemistry & Chemical Biology (2016-) 4. Interim Chair, Department of Chemistry & Chemical Biology (2016) 5. Interim Director, Barnett Institute for Chemical and Biological Analysis (2016-) 6. Departmental Grant Review Team (Founder, Chair 2015-). 7. University Laboratory Safety Hygiene Committee (2009-2012), Chair (2015-2016) 8. Reviewer, Shevell/Cohen Cancer Research Fund, Department of Pharmaceutical Sciences (2015) 9. Reviewer, Neumeyer Research Achievement Award, Department of Pharmaceutical Sciences (2015) 10. Empower Campaign Participant Dubai, Philadelphia (2015), Hong Kong, & Washington, DC (2014) 11. Department Merit Review Committee (2015) 12. Founder and Lead for the Northeastern University Global Health Initiative (2011- ) 13. Chair, Global Health Fridays Seminar Series (2013-) 14. Graduate Admissions Committee (2010-2011, 2012-2014) 15. Research Policy Oversight Committee (President’s Representative, 2011- 2013) 16. Global Health Initiative Cluster Hire Chair (2011-2013) 17. College of Science Chemical Hygiene Officer Search Committee (2012) 18. Graduate Student Seminar Committee Member (2009); Chair (2010-2012) 19. Drug Discovery Cluster Hire Committee Advisor (2011) 20. Chair, Provost’s Committee for Chemical Inventory System Implementation (2010-2011) 21. Northeastern University Technology Transfer Advisory Group (2010) 22. Instrumentation Committee (Boston University, 2008-2009)

Service to the Scientific Community. Scholarly Journals: Editing and Peer Reviewing 1. Scientific article reviewer (141 articles reviewed, as of 11 Nov 2017) ACS Books (1), ACS Central Science (1), ACS Infectious Diseases (3), ACS Medicinal Chemistry Letters (12), Antimicrobial Agents and Chemotherapy (4), ACS Combinatorial Science (4), Beilstein Journal of Organic Chemistry (3), BioMed Central Research Notes (1), Bioorganic and Medicinal Chemistry (3), Bioorganic and Medicinal Chemistry Letters (13), Chemical Biology & Drug Design (31), ChemBioChem (1), ChemMedChem (3), Combinatorial Chemistry & High Throughput Screening (1),Current Medicinal Chemistry (1), Drug Discovery Today (2), European Journal of Medicinal Chemistry (11), FEBS Microbiology (1), Future Medicinal Chemistry (2), International Journal for Parasitology: Drugs and Drug Resistance (1), Journal of the American Chemical Society (1), Journal of Clinical Endocrinology and Metabolism (2), Journal of Medicinal Chemistry (25), MedChemComm (4), Molecular Diversity (1), Nanomedicine (1), Nature Chemistry (1), Nature Reviews Drug Discovery (1), Pharmaceutical Research (1), PloS Neglected Tropical Diseases (12), PLoS Pathogens (1), Tetrahedron Letters (1), Trends in Parasitology (1). 2. Chemical Biology & Drug Design Editorial Board, (2007-) 3. ACS Infectious Diseases Editorial Board (2015-) 4. Drug Repurposing, Rescue, & Repositioning Editorial Board, (2014-2016) 5. Associate Editor (2013-present) and Guest Editor (2011-2013) – PLoS Neglected Tropical Diseases. 6. Guest Editor, Special issue: “Phenotypic Drug Discovery”, MedChemComm, (2016). http://rsc.li/2ddxBDu

Grant Proposal Peer Reviewer 1. Dana-Farber Cancer Institute/Northeastern University Joint Program in Cancer Drug Development (2014). 2. L'Agence Nationale de la Recherche (ANR, France; 2014) 3. Military Infectious Diseases Research Program (MIDRP) (2013-2014) 4. National Institutes of Health Study Section Reviewer • 2018/01 ZRG1 BCMB-H (02) NIH-NIAID SBC-A (R01). October 2017 • 2017/10 ZAI1 AMC-M (C3) NIH-NIAID Nonclinical Services for Development of Interventional Agents for Infectious Diseases. Review panel chairperson • NIH-NIAID Pathway to Independence Award (Parent K99/R00), June 2016. • F04A-W(20)L Fellowships: Synthetic and Biological Chemistry, June 2015. • ZAI1 LR-M M1-1 R21/R33 NIAID Development of Novel Therapeutics for Select Pathogens (Influenza), March 2015. • ZAI1 LR-M M1-1 R21/R33 NIAID Development of Novel Therapeutics for Select Pathogens (Bacteria), March 2015 • U19 NIAID Centers of Excellence in Translational Research (CETR), July 2013 • ZAI1JKBMJ6 Partnerships for Interventions to Treat Chronic, Persistent and latent Infections, December 2012 • IMST-G Small Business: Biological Chemistry, Biophysics, and Drug Discovery, June 2012 • IMST Small Business Biological Chemistry, Biophysics, and Drug Discovery, January 2012 • Tropical Medicine Research Center P50 Study Section, September 2011 • NIAID Special Emphasis Panel for Unsolicited P01, September 2011 • NIAID Preclinical Services for the Development of Interventional Agents for Infectious Diseases, May 2011 • IMST Drug Discovery and Development SBIR Grants, July 2010 • NIAID Special Emphasis Panel on Product Development Public-Private Partnerships, March 2010 5. SeedingLabs (2013) 6. Medical Research Council (MRC) (2013, 2014) 7. Wellcome Trust – Seeding Drug Discovery (2014) and Strategic Award (2015) programs 8. State of Florida Department of Health – Zika Research Grant Initiative (2016)

Conference Organizing Committees 1. Medicinal Chemistry Gordon Research Seminar (Vice-Chair 2015; Chair 2016) 2. Applied Pharmaceutical Conference (2011-2014) 3. Medicines for Neglected Disease (MeND) Workshop, Boston University (2010) Teaching Courses and Workshops (asterisk indicates new course preparation)

Brandeis University – Courses Taught 1. Summer 2006 RCHE101-01 General, Organic & Biochemistry* 2. Spring 2007 RCHE101-01 General, Organic & Biochemistry 3. Fall 2007 RCHE101-01 General, Organic & Biochemistry 4. Spring 2009 RCHE101-01 General, Organic & Biochemistry

Northeastern University – Courses Taught (Teaching Effectiveness Score from student evaluations out of 5.0) 1. Fall 2009 CHEM 2315 Organic Chemistry I for Chemistry Majors * (3.6) 2. Fall 2010 CHEM 2315 Organic Chemistry I for Chemistry Majors (4.8) 3. Spring 2011 CHEM 2311 Organic Chemistry I (4.7) 4. Fall 2011 CHEM2315 Organic Chemistry I for Chemistry Majors (4.9) Recipient of the University Excellence in Teaching Award 5. Spring 2012 CHEM5676 Bioorganic Chemistry* (4.8) 6. Fall 2012 CHEM2315 Organic Chemistry I for Chemistry Majors (5.0) Nominated for the University Excellence in Teaching Award 7. Spring 2013 CHEM2313 Organic Chemistry II* (4.0) 8. Spring 2013 CHEM5676 Bioorganic Chemistry (4.9) 9. Spring 2014 CHEM2313 Organic Chemistry II (4.8) 10. Fall 2014 CHEM2315 Organic Chemistry I for Chemistry Majors (4.7) 11. Spring 2015 CHEM5676 Bioorganic Chemistry (4.8) 12. Spring 2016 CHEM2317 Organic Chemistry II for Chemistry Majors (4.7) 13. Spring 2017 CHEM2313 Organic Chemistry II (Honors) (4.9) 14. Fall 2017 CHEM1000 Introduction to Chem & Chem Bio at Northeastern 15. Fall 2017 CHEM4750/4770 Chemistry Capstone/Senior Research

Northeastern University – Other Teaching 1. Spring 2010. PHSC 6290 Biophys Methods in Drug Discov – guest lecturer 2. Fall 2010 CHEM 8504 Graduate Seminar 3. Nov 2010 Pfizer-Northeastern University Green Chemistry Workshop 4. Spring 2011 CHEM 8504 Graduate Seminar 5. Jan 2011 CHEM5676 Bioorganic Chemistry – guest lecturer 6. Fall 2011 CHEM8504 Graduate Seminar 7. Spring 2012 CHEM8504 Graduate Seminar

Current Research Students Postdoctoral Associates Undergraduate Students Melissa Buskes (2017-) Jack Fisher (2016-) Hitesh Jalani (2017-) Jeremy Armand (2017-) Doctoral Students Brady Greene (2017-) Dana Klug (2013-) Mitch Rivers (2017-) Kelly Bachovchin (2015-) Andrew Spaulding (2016-) Westley Tear (2016-)

Past Research Students Postdoctoral Associates, position after completion of training Poornachandran Mahalingam (2015-), Mersana Therapeutics, Scientist Baljinder Singh (2015-2017), Northeastern University, Associate Research Scientist Lori Ferrins (2015-2016), Northeastern University, Associate Research Scientist Seema Bag (2013-2015), Northeastern University, Associate Research Scientist David Finnegan (2011-2014), Boston Biomedical, postdoctoral researcher Joao da Silva (2011-2013), GlaxoSmithKline, Inc., staff scientist Sandra Luongo (2011-2013), Imperial College, postdoctoral researcher Emanuele Amata (2011- 2013), University of Catania, research faculty Gautam Patel (2011- 2012), Zydus Cadila, senior scientist Adam Lesser (2011- 2012), Athena Health, analyst Cuihua Wang (2009- 2011), Massachusetts General Hospital, research fellow Caitlin Karver (2009- 2011), DePaul University, assistant professor Trent Ashton (2008- 2009), Monash Institute of Pharm. Sciences, research fellow Graduate Students, position after graduation. Gengyang Yuan, PhD (2016-2017), postdoctoral, Massachusetts General Hospital Meaghan Sbeika Fellano PhD (2016-2017), Pearson Enrico Mongeau, PhD (2016-2017), Northeastern University. Naimee Mehta, PhD (2012-2017), postdoctoral, University of North Carolina-Chapel Hill Chiara Chapman, PhD (2016) Ian Doxsee, MS (2016), Gilead, Inc. Megan Sheehan, MS (2016), H3 Biomedicine, Inc. Allison Murdza, MS (2016), Merck, Inc. Angela Tanner, MS (2012-2015), student, Massachusetts College of Pharmacy William Devine, PhD (2011-2015), postdoctoral, Boston University Jennifer Woodring, PhD (2011-2014), postdoctoral, The Scripps Research Institute Elizabeth Jones, MS (May 2011-2014), Ensemble Therapeutics Uma Swaminathan, MS (2012-2014), Dana-Farber Cancer Institute Zeke Clements, MS (2012- 2013), Novartis Stefan Ochiana, PhD (2009- 2012), postdoctoral, Columbia University Zhouxi Wang, PhD (2010- 2012), postdoctoral, National Institutes of Health Lisseth Silva, MS (2012-2015), Massachusetts General Hospital Cheri Snedeker, MS (2010- 2012), Ensemble Therapeutics, Inc Bianca Perez, MS (2009- 2010), doctoral student, Universidade do Porto Undergraduate Students, position after graduation or departure from lab Kate Schneider (2017). Current undergraduate student Stephen (Cole) Rougas (2017). Current undergraduate student Vivan Hilborne (2014-2017), Current undergraduate student Travis DeLano (2014-2017), Caltech, PhD program in Chemistry Melanie Frische (2015-2017), Current undergraduate student Laura Tchiegg (2015-2016), Novartis, Inc. Stephen Ejk (Jan 2013-2015), University of Chicago Medical School, medical student Asel Primbetova (2014), Undergraduate student Charles Hoyt (2012-2013), University of Basel, PhD program Cristin Juda (2010- 2013), Harvard University, PhD program in Chemistry Anthony Varca (2013), Dana Farber Cancer Institute, researcher Brian Coffey (2010- 2013), Tufts University Medical School, medical student Peter Edwards (2011- 2013), Univ. of British Columbia, PhD program in Chemistry Mitchell Gallerstein (2013), Current undergraduate student William Smith (2012), Dana Farber Cancer Institute, researcher Emily Blazensky (2011- 2012), Social media consultant Timothy Hopper (2010- 2012), Boston College, PhD program in chemistry Katherine Spring (2011), Tufts University School of Veterinary Medicine Joel Beatty (2011), University of Michigan, PhD program in Chemistry Michael Russo (2009, 2011), Northeastern University, admissions counselor Craig Tallman (2010), Air Compliance Group LLC, air quality tester Matthew Stevenson (2009), Conde Nast, consultant Doctoral and Master’s Degree Committee Membership Northeastern University Rane Harrison (PhD, 2017) Cynthia Lichorowic (PhD, 2016) Iredia Iyamu (PhD 2016) Emily Stoler (PhD, 2015) Wanlu Qu (PhD, 2015) Pei Shi (PhD, 2015) Nadeesha Ranasinghe (PhD, 2014) Chao Chen (PhD, 2014) Michael Cuccarese (PhD, 2014) Yanping Wang (PhD, 2014) Dunesh Kumari (PhD, 2014) Emily Corcoran (PhD, 2014) Fengfai (Julia) Yan (PhD, 2013) Patrick Weiser (PhD, 2013) SuLi Liu (PhD, 2013) Chen Li (PhD, 2013) Yue Zhang (PhD, 2013) Fatmae Tousi (PhD, 2013) Michael Placek (PhD, 2013) Roushan Afroze (PhD, 2012) Rose Gathungu (PhD 2012) Yi Wang (PhD, 2012) Shama Bajaj (PhD, 2012) Lenny Dao (PhD, 2012) Meghan Johnson (PhD, 2011) Rhiannon Thomas (MS, 2011) Andrea Lebed (MS, 2010) Vaneet Sharma (PhD, 2010) Boston University Ashley Parks (PhD, 2012) Kimberly Holte (PhD, 2011) Yu Chen (PhD, 2009) Amal Ting (PhD, 2009) Xiang Liu (PhD, 2008)

External Dissertation Examiner Triveni Rajkumar Pardhi (National Institute of Pharm Ed and Res, Gujarat, India) Linley Barnard (MS degree, University of Cape Town, 2017) Harriet Newson, (University of Western Australia, 2017) Anija Mol T Philip (Indian Institute of Technology – Kanpur, 2016) Chimed Jansen (VU University Amsterdam, 2015) Jacob Nankervis (Monash University, 2012) Timothy Blackmore (Monash University, 2012) K. Ravi (Institute of Technology Karnataka, 2009)